reason report
look diamond rough initi coverag
bottom line believ sector like remain
pressur forese futur price headwind
unlik eas anytim soon especi gener compani
still process evolv portfolio higher valu durabl
asset high debt burden may limit near-term cash deploy
altern least compani thu recommend
select particip sector compani rel
differenti portfolio improv balanc sheet expand
margin look potenti consolid evolut portfolio
durabl asset get construct sector
initi coverag outperform rate four
stock ipxl under-perform rate
one teva market perform rate four stock
catalyst watch includ ph data
heron post-op pain outcom jazz
litig later gener filer xyrem visibl
resolut endo mesh litig potenti approv
gener version advair proair
favorit name pt durabl xyrem
franchis line extens strategi pipelin growth strong
amneal transact chang impax long-term sale growth margin
profil believ sale grow heron
pt in-lin consensu cinv franchis
see upsid consensu sale mainli
post-op pain see phase data
least favorit name teva teva pt still see
downsid number beyond expect debt load
remain overhang
compani inform leerink partner llc research
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
januari pm edt rx trend deriv im health
initi coverag specialti pharmaceut gener
look diamond rough
spec pharma/gener fundament like remain pressur
continu price headwind payer pressur unlik eas soon especi gener
product portfolio still process evolv higher valu durabl asset
high debt burden limit near-term cash deploy altern compani
recommend select particip compani sustainable/differenti
pt xyrem durabl appreci given line extens
strategi npv vs con pipelin balanc sheet enabl
diversif away xyrem time estimate pipelin drive sale
pro-forma compound-annual-growth-rate margin profil differenti
pipelin cost synergi improv oper margin
heron pt in-lin consensu chemotherapi induc nausea
vomit cinv product posit ph data post-op
pain expect estim sale vs impli current stock
endo pt believ addit mesh litig liabil unlik
larg anticip expect drive multipl expans continu
busi execut believ consensu estim achiev
teva teva pt still see downsid number beyond
expect debt load remain overhang
leerink partner research compani report factset
macro pressur continu forese futur
gener price eros high-singl low-doubl digit rang like
continu near term due faster fda approv continu
brand payer like continu leverag formulari tier
coinsur etc put pressur price util
gener competit like remain strong
fda focus approv sever manufactur product
addit manufactur continu enter us market
specialti pharma compani like increasingli compet
fda commit approv generic/biosimilar
fda continu exercis high regulatori cgmp standard
trump administr remain commit repeal replac
howev given pace develop far
anticip signific chang forese futur
believ spec pharma/gener stock trade macro
company-specif catalyst
revenu
improv
improv
scaleupside/ downsid leerink revenu ep estim rel consensusnear term catalyst may meaning /- impact stockbal sheet flexibility leverag balanc sheet capit deploy base metric chang leverag ratio chang yieldvalu upside/ downsid leerink valuat estim rel stock price valuat methodolog
ev/ebitda multipl
sector valuat impact macro
base ebitda mix
trend price regul etc
gener compani also
branded/otc busi
differ growth margin profil
return excess
heterogen mix compani
macro trend relev less
growth low-doubl digit
rel individu compani
sever compani cash flow
specialti pharma gener coverag univers
consensu number may updat amneal transact
includ averag subset consensu updat estim amneal transact
con updat scmp acquisit
marketstockcappricelp vslp vsvaluationimpli lpcon con enueepsebitdabasisleerinkcurr yrsmylanmylmarket ratinglp ptstock epsleerink vs leerink vs ev/ebitda summari stock pick
profit risk
tabl content
view industri
stock-specif rate along stock select criteria
view industri
stock-specif rate along stock select criteria
gener industri signific pressur
past year
stock price chang vs price
rel price chang dec
gener multipl saw signific contract vs
sinc trade correl
higher multipl driven
slower fda approv
favor price
volum scenario certain
upcom loe sever
lower multipl driven
signific payer consolid
approv fda
increas competit
multipl go
gener index calcul use weight averag roll forward ev/ebitda multipl
gener index includ teva ipxl prx hsp wpi note loe loss exclus
seen multipl downward revis revenu
ep estim
revenu chang dec
ep chang dec
expect downward pressur earn
continu forese futur
similar trend estim although downward
revis smaller
revenu chang
ep chang
ev/ebitda multipl necessarili declin
ev/ebitda spread
fundament improv
gener sector multipl high correl price
trend past year
correl monthli nadac y/i chang x-axi forward ev/ebitda gener multipl y-axi
price eros remain high-single/low-doubl digit
multipl could remain range-bound
chang
rang
expect gener
multipl
price
simpl averag calcul give ndc code equal weight factset nadac price data
greater anda approv alreadi generic market
result price headwind
anda approv increas year
mix first time approv declin
later
fda gov leerink partner analysi
custom consolid past year
omnicar
reach
partnership form claruson
cardin form
result total volum concentr among player
volum
consist independ format claruson
number manufactur still remain
fragment increas new entrant
top compani suppli volum
number manufactur continu grow
total number gener manufactur per im
trx
ltm
solco subsidiari huahai one top
stake steril inject leader gland pharma
pharma ritedos last year
im health compani report leerink partner analysi
number gener market entrant given
product increas nadac price subsequ declin
exampl product competitor increas
correspond decreas nadac report price
im health nadac price data leerink partner analysi
medacorp specialist indic payer pressur like
abat go forward price unlik go
first break class trade
mail order retail
follow suit non-own
set negoti price
combin retail distribut
drive one lowest price
mckesson rite aid didnt see valu
expect mckesson
mckesson unclear saw better valu
vs rite aid combo
benefit price
equal expect
alreadi good price
independ potenti
signific price reduct
continu consolid dont expect
price pressur eas anytim soon
compani report medacorp interview leerink partner analysi
expect price eros high-single/low-doubl digit rang
result gener multipl like remain rang
correl monthli nadac y/i chang x-axi forward ev/ebitda gener multipl y-axi
price eros like
remain high-
multipl
continu expect industri remain
pressur forthcom pipelin opportun lower
opportun
unlik larg
report im
truvada spiriva
latuda
unlik go gener
year combin
ltm im sale
like
strong year believ
sector multipl reflect
declin opportun
sale year prior expiri use year sale june use year
multipl expans unlik industri like continu
face high competit diminish opportun set
continu look
effici
integr
vertic drive
threat new entrant
barrier entri remain low
larg number gener supplier
mani new supplier continu
enter us market
threat substitution/regul
brand lose exclus like
regulatori hurdl remain high
fda commit new approv
past year
put consider
expect
pressur continu
dont expect
get wors
consolid
like slow
compani report leerink partner analysi
outlook recommend invest sector
downward pressur revenu like continu
gener sector multipl like remain range-bound
unless see
right-siz portfolio
disrupt distributor/custom channel
 pipelin
recommend select particip sector
compani outperform sector one
valuat methodolog base sotp ev/ebitda multipl
rational use sum-of-the-part sotp analysi reflect hybrid busi segment compani
differ multipl gener specialti consumer/otc busi trade util ev/ebitda
abl compar compani differ level balanc sheet leverag use multipl
reflect expect return next month
multipl in-lin current ev/ebitda estim
believ ipxl deliv top-lin growth warrant
premium peer
believ addit mesh payment less
anticip drive slight increas multipl
expect slight expans multipl make progress
complex gener advair insulin/biosimilar
dont expect larg differ multipl current
level in-lin consum peer
assum downward revis top line also yield
multipl contract current level
downsid
adj con
in-lin con
in-lin con
in-lin con
ep
leverag ratio
leverag ratio
leverag ratio
declin
plu
visibl
visibl new
visibl approv
gx proair approv
gx advair
gx copaxon
con resp
leverag ratio
laboratori catapult industry-lead portfolio
profit growth
combin amneal chang top-
line growth profil
oper margin improv low-mid-
teen driven
addit higher margin amneal busi
bp impax brand/gener hybrid biz
synergi amneal combin
adjust consensu includ impact amneal transact
see strong profit cash flow drive
improv leverag
provid manag
flexibl deploy capit drive sharehold valu
multipl deriv pt
ebitda impli
market view
visibl drive ipxl higher
current multipl
share count post amneal close increas share outstand
closur deal amneal
patent litig decis rytari
approv gener copaxon
risk invest thesi valuat
limit visibl composit amneal
save delay lower expect
amneal transact chang impax long-term sale growth profil drive
margin expans newco leav flexibl addit capit deploy
compani report factset leerink partner estim note market cap million average volum thousand deriv current stock price con ev/ebitda multipl
vs adjust vs leerink view ipxl
downsid
consensu rang broad estim includ impact amneal deal
pro-forma sale combin busi grow vs pro-
sale compound-annual-growth-rate pro-forma driven new gener launch
off-set high-singl digit base gener eros
gross margin expans driven cost
effici improv product mix
oper margin expans driven
synergi stand-alon amneal deal
ep grow compound-annual-growth-rate
deal close newco like total debt
leverag ratio declin
strong balanc sheet along run-rat post deal close
support addit busi develop
increment visibl potenti pipelin launch perform key base
busi gener product concerta adrenaclick gx voltaren gel yuvafem
gx opana er provid visibl newco growth potenti
use weight averag ev/ebitda multipl in-lin current
level higher peer ebitda deriv pt
compani report leerink partner estim
endo pharmaceut upsid possibl margin improv
multipl expans improv clariti mesh litig
ep expect declin y/i
well understood investor
see compound-annual-growth-rate
believ endo meet consensu sale
ep
addit mesh litig liabil unlik
larg expect conserv
includ addit
announc august believ
drive multipl expans stock
yield expand
get closer resolut
mesh litig
slightli higher ebitda vs
consensu along expans
ev/ebitda multipl
drive upsid stock pt
sale con due lower
updat mesh litig posit
litig vs hospira adrenalin
risk invest thesi valuat
faster expect eros vasostrict
mesh litig remain drain cash
delay time new gx launch
investor gain visibl pipelin conclus mesh
litig expect expans endp multipl
compani report factset leerink partner estim market cap million average volum thousand
vs vs leerink view endo
downsid
revenu vs con in-lin vs con
expect declin compound-annual-growth-rate
gross margin increas
oper margin remain rang
ep in-lin con expect
declin compound-annual-growth-rate
net debt
net debt/ebitda ratio declin
assum cumul mesh payment
addit announc august
mesh payment expect cumul gener
updat litig mesh testosteron
litig vs hospira adrenalin
visibl fda requir approv xiaflex cellulit
believ stock current level reflect ebitda
expect
howev get greater visibl resolut litig
proceed expect increas multipl impli
multipl current level
compani report factset leerink partner estim
interest pipelin larg reflect stock
current level view
strong pipelin gener insulin/biosimilar
off-set continu high-singl digit
base gener eros support revenu growth
potenti near-term upsid consensu
number limit competit copaxon
advair difficult visibl
line sale
ep mostli due share buyback
balanc sheet give option capit
deploy hit ep
biosimilar growth driver could
expand multipl rel peer
multipl slight expans current
level ebitda line
consensu deriv pt
like fda approv gener advair
like fda approv biosimilar neulasta white
like us launch biosimilar herceptin
breast gastric cancer late
risk invest thesi valuat
gener advair may get approv
limit visibl time new gener
advair approv may drive near-term upsid mostli priced-in look
improv visibl long-term pipelin includ biosimilar
compani report factset leerink partner estim market cap million average volum thousand
vs vs leerink view
downsid
revenu vs consensu in-lin vs
con expect grow compound-annual-growth-rate
gross margin increas
trend back
oper margin improv rang
ep line vs con vs con
expect grow compound-annual-growth-rate
net debt ebitda leverag
gener net debt payment give
ampl flexibl share buy-back hit ep target
fda approv gener advair like
fda approv biosimilar neulasta like
us launch biosimilar herceptin settl term undisclos
assum launch
ebitda line consensu
expect current stock level get greater visibl
gener advair approv insulin/biosimilar launch
expect multipl expans
compani report leerink partner estim
look better visibl long-term growth driver stock
consum healthcar america chca like
continu grow low-singl digit
consum healthcar chci grow
low-singl digit growth potenti
manag initi take time play
rx potenti upsid consensu perrigo
launch proair androgel
limit visibl outer year
see improv profit leverag ratio
strong cash flow allow
look potenti bolt-on acquisit
launch gener proair androgel
appoint new ceo
multipl deriv pt
roughli in-lin con ebitda
current multipl
risk invest thesi valuat
delay new rx over-the-counter product launch
initi drive busi may
success anticip
limit visibl medium-/long-term growth trajectori busi dont
see high potenti out-performance drive stock meaning higher
leerink partner estim factset consensu note market cap million average volum thousand
vs vs leerink view
downsid
sale vs consensu revenu expect grow
compound-annual-growth-rate vs consensu
gross margin increas modestli
oper margin improv
ep expect grow compound-annual-growth-rate
vs consensu
debt-to-ebitda ratio
debt paid result net debt
annual start onward
enabl manag explor sever opportun buy back
share and/or pay debt
launch gener proair androgel
appoint new ceo addit clariti compani medium-/
use weight averag ev/ebitda multipl in-lin
current level ebitda deriv pt
compani report leerink partner estim
effort remain concern execut risk high debt burden
follow teva announc restructur
plan believ con high
expect competitor copaxon
expect total us gener biz erod
compound-annual-growth-rate vs con
strong execut sever front need
right-siz busi
base reduct
number year
sale con copaxon gener
capital-expenditure reduct vs
austedo fremanezumab grow
approv addit copaxon gener
debt load remain overhang
potenti strateg outlin new
despit cost reduct dividend suspens
believ teva need refin debt
next year maintain min cash balanc
settlement work capit disput vs
risk invest thesi valuat
ebitda con
ev/ebitda multipl contract
drive stock lower pt
higher expect new gx launch
brand product austedo fremanezumab
perform expect
despit recent downward estim revis see downsid
number expect debt load continu put pressur stock
leerink estim factset note market cap million average volum thousand
vs vs leerink view teva teva
downsid
revenu vs con vs con
expect declin compound-annual-growth-rate
gross margin decreas
oper margin declin
improv outer year cost reduct portfolio
ration growth brand product
ep in-lin con con
expect declin compound-annual-growth-rate
net debt ebitda leverag remain high level
declin in-lin manag guidanc
annual need pay debt due
year deplet cash
addit detail new manag strateg vision includ updat
restructur initi could rebuild investor confid near term
approv addit copaxon gener could prove headwind
believ stock current level reflect ebitda
current expect
continu pressur busi overhang debt
burden expect see ev/ebitda multipl contract
compani report factset leerink partner estim
addit strateg outlin new ceo kre schultz
potenti approv gener rytari post stay
potenti updat manag rate
addit case file mesh litig
patent litig decis rytari
fda approv gener proair
launch gener androgel
tabl content
view industri
stock-specif rate along stock select criteria
view industri
stock-specif rate along stock select criteria
follow in-lin perform saw sizabl
downtick spec pharma multipl recent month
specialti pharma index calcul use weight averag roll forward ev/ebitda multipl
specialti pharma sector heterogen mix
compani limit common across portfolio
compani report leerink estim
consist indic across neurolog nephrolog rheumatolog pulmonolog ophthalmolog
multipl downward revis revenu across
group compani
revenu chang dec
factset leerink analysi
estim
declin
least past
estim heron
come
significantli
stabil past
heron like see revenu upsid vs con
resolut oper issu xyrem defitelio growth new
product launch drive upsid consensu near term
heron upsid sale outer year post-oper
pain lp vs impli current stock level
factor eros acthar inomax believ
reflect consensu clear disconnect buy-sid expect
sell-sid publish number view
pacira roughli in-lin consensu exparel sale
compani report factset leerink estim note chang leerink estim vs consensu con updat scmp acquisit
revenueleerink estcon changeleerink estcon changeleerink estcon changecompanyleerinkstock rate valuat methodolog base dcf
rational specialti pharma coverag includ heterogen mix compani compani
earli stage neg cfo addit believ company-specif driver pipelin
intellectu properti balanc sheet etc would meaning impact valuat thu believ dcf
methodolog appropri
assum termin growth reflect addit
year past vyxeo next-gen
sodium oxyb sale growth patent expiri
forecast reflect patent
life includ termin valu
addit disclos pipelin
assum termin growth reflect
continu eros acthar inomax
gener busi outer year partial off-set
pipelin growth
forecast past assum
loe exparel assum termin
growth reflect continu impact competit
leerink estim wacc base bloomberg valu discount rate reflect blend rate stand-alon wacc sucampo
addit revenu evalu stock across
downsid
con
revenu ep
in-lin con
con
annual
debt
leverag ratio
stay
invest
leverag ratio
litig trial updat
updat develop
acthar praxair
cinv product
pharmaceut durabl xyrem franchis
diversif pipelin outer year underappreci
durabl xyrem franchis underappreci
npv xyrem consensu
ip strategi gener filer give
time execut next-gen strategi
base medacorp survey believ
xyrem line extens support annual
franchis sale despit
entri gener and/or once-nightli
sodium oxyb
pipelin help diversifi busi
mix xyrem sale declin
strong cash flow low debt burden give
flexibl augment pipelin
deriv pt base dcf valuat
use wacc termin growth
rate project
consolid district court litig case xyrem
amneal lupin teva
addit visibl next-gen xyrem
risk invest thesi valuat
lose xyrem litig remain
faster eros brand xyrem
trigger earlier entri gener
xyrem growth slow see upsid durabl xyrem franchis
strong pipelin balanc sheet support portfolio diversif
leerink estim factset note market cap million average volum thousand
vs vs leerink view
downsid
revenu vs con vs con
compound-annual-growth-rate
gross margin mostli flat
oper margin improv take step
due gener competit xyrem
ep vs con vs con
expect grow compound-annual-growth-rate
net debt ebitda
net debt outstand along
ampl flexibl acquir addit
consolid district court litig case xyrem amneal lupin
teva
ph data avadel sodium oxyb
sale ramp vyxeo
visibl next-gen sodium oxyb
dcf analysi use wacc termin growth
rate yield price target
cash flow reflect impact competit brand
gener xyrem franchis well launch next-gen version
compani report leerink partner estim
heron pharmaceut commerci potenti
in-lin consensu cinv product --
sustol cinvanti
upsid stock could come
post-op pain see ph data
believ grow sale
vs impli current stock level
driven
long-act post-op pain relief
potenti signific share orthoped
procedur especi painful/costli
consensu sale mainli due
data tka studi local administr
deriv pt use dcf project
cash flow patent
expir use wacc termin valu
dcf consensu outlook
npv roughli in-lin
cinv franchis
risk invest thesi valuat
sustol growth trajectori impact
ph data robust expect
addit financ need
leerink estim factset note market cap million average volum thousand
posit clinic data could drive stock
vs vs leerink view heron
revenu vs con vs con
expect sale vs con
driven
gross margin expans
oper turn profit get first full year sale
capit rais recent announc anticip cash
believ capit rais adequ approv launch
assum heron launch product along
continu commerci support cinv product
expect sever catalyst come month includ
sever data readout
sale ramp two cinv product
roughli in-lin consensu cinv product believ
data key driver stock remain
downsid
dcf-base valuat point upsid current level
project cash flow last patent termin valu
also account addit share issu decemb
wacc
compani report leerink estim assum heron realiz offer plu addit share
declin cow reflect
project top-lin growth
like consensu mainli
conserv acthar inomax sale
sever regulatori commerci hurdl
could prevent rapid eros acthar
assum share eros acthar
inomax interestingli
believ key overhang
stock consensu estim still assum
eros either two product
pipelin unlik diversifi busi
meaning sever year estim pipelin
drive sale
leverag ratio follow
sucampo transact remain
focus debt paydown
dcf analysi base discount rate
termin growth rate yield price
target moder current stock valu
consensu number assum eros acthar inomax
updat potenti acthar competitor
approv praxair gener inomax
ph data
risk invest thesi valuat
greater expect delay entri acthar
win appeal inomax ip case
look better visibl acthar emerg competitor develop
praxair gener inomax get construct stock
leerink estim factset note market cap million average volum thousand
consensu includ contribut sucampo acquisit
vs vs leerink view
downsid
compani report leerink partner estim
consensu yet updat sucampo acquisit reflect
potenti eros acthar inomax competit
revenu repres compound-annual-growth-rate
gross margin in-lin level declin
acthar inomax sale erod
oper margin declin due
increas pipelin sg invest
ep overal flat compound-annual-growth-rate growth
net debt current market cap
debt-to-ebitda ratio stay
annual like primarili focus
reduc debt load expect
regulatori develop acthar competitor
potenti gener approv appeal decis patent litig case vs
praxair late
visibl near-term acthar growth
pipelin develop stansoporfin
dcf analysi yield price target
use discount rate termin growth rate reflect
continu eros acthar inomax gener busi
pacira exparel grow near term potenti face
competit heron outer year
expect sale growth
mainli due collabor in-
line consensu slow outer year
due potenti competit heron
sale growth near term could come
increas penetr orthoped surgeri
collabor
nerv block approv expand indic
drive usag among anesthesiologist
risk-adjust sale
increas penetr soft tissu
market addit ph data
long-term growth may impact entri
heron better clinic profil longer
efficaci easier administr
pt base dcf forecast cash
flow use wacc
exparel sale see near-term upsid
salesforc logarithm larger pacira salesforc
adcom nerv block indic feb
ph readout c-section studi
exparel get approv nerv block
ph studi success
limit impact collabor
potenti competit heron
near-term overhang upcom adcom nerv block howev
collabor drive growth exist indic
logarithm larger- pacira state exact number rep take part co-promot competitor healthcar confer sept
leerink estim factset note market cap million average volum thousand
vs vs leerink view pacira
downsid
compani report factset leerink estim
revenu in-lin con
expect grow
gross margin increas modestli
ep slightli consensu
cash short-term invest debt
grow
enabl manag explor busi develop
risk-adjust nerv block revenu ahead nerv
block adcom pdufa feb april respect
c-section result posit drive penetr soft
forecast cash flow
use wacc termin growth rate reflect eros
deriv valuat use dcf
outer year potenti competit
ph data
visibl near-term acthar growth
sale ramp cinvanti sustol
ph data
xyrem patent trial/potenti settlement prior trial
xyrem low sodium ph data
ph result avadel once-nightli sodium oxyb
appeal decis litig vs praxair
fda approv acthar competitor ani depom
tabl content
view industri
stock specif rate along stock select criteria
view industri
stock specif rate along stock select criteria
number except per share data
number except per share data
restrict cash cash equival
prepaid expens current asset
asset held sale
account payabl accru expens
current portion legal settlement
current portion ltd
liabilit held sale
number except per share data
adjust reconcil ni net cash oper
amort debt issuanc cost discount
provis bad debt
provis inventori reserv
net loss dispos pp
chang fair valu conting consider
loss extinguish debt
prepay penalti ltd
sale busi asset
decreas increas work capit
purchas properti plant equip capital-expenditure
acquisit businesses/asset net cash acquir
patent acquisit cost licens fee
proceed sale busi
increas restrict cash cash equival
net invest
net oper invest
borrow repay revolv credit/oth net
payment conting consider
tax benefit share award
payment tax withhold restrict share
exercis option
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
unrestrict cash
number except per share data
gener administr
sale market
number except per share data
prepaid expens
properti equip net
accru payrol employe liabil
current portion defrer revenu
promissori note payabl relat parti
accumul comprehens loss
number except per share data
adjust reconcil ni net cash oper
amort debt discount
impair loss properti equip
loss gain dispos fix asset
amort premium short-term invest
decreas increas work capit
purchas short term invest
matur short term invest
purchas properti equip
proce sale proprti equip
net invest
net proce sale common stock and/or pre-fund warrant
proce stock option exercis
proce purchas employe stock purchas
proce issuanc promissori note payabl relat parti
net financ
net chang equival
number except per share data
number except per share data
prepaid expens current
accru profit share royalti
current portion ltd
number except per share data
adjust reconcil ni net cash oper
tax expens stock option rsa
accru profit share royalti expens net payment
reserv ture receiv
sale asset
loss extinguish debt
net chang fair valu deriv
recognit defer revenu
decreas increas work capit
payment busi acquisit
purchas properti plant equip capital-expenditure
payment licens agreement
invest cash surrend valu insur
proce repay tolmar loan
proce sale intang asset
maturities/purchas short-term invest
net invest
payment defer financ fee
purchas bond hedg deriv asset
proce sale warrant
tax benefit stock option rsa
proce exercis stock option espp
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
equiti loss investe
number except per share data
number except per share data
adjust reconcil ni net cash oper
loss extinguish debt
loss dispos properti equip
provis loss account receiv inventori
amort debt discount defer financ cost
decreas increas work capit
acquisit net cash acquir
acquisit intang
acquisit invest
acquisit in-process
proceed sale busi
purchas properti plant equip capital-expenditure
net invest
proce issuanc debt/ repay
borrow repay revolv credit/oth net
proce employe incent plan share award
acquisit non-controlling interest
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
number except per share data
prepaid expens
asset held sale
current matur ltd
accru payrol payroll-rel cost
accru current liabilit
current liabil held sale
pension postretir benefit
ordinari share held treasuri cost
number except per share data
adjust reconcil ni net cash oper
dispos discontinu oper
decreas increas work capit
chang account receiv
chang inventori
chang account payabl
chang incom tax
chang
purchas properti plant equip capital-expenditure
acquisit intang net cash acquir
proce dispos discontinu oper net cash
net invest
proce exercis share option
repurchas share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
number except per share data
royalti
number except per share data
prepaid expens
current portion defrer revenu
accumul comprehens loss
number except per share data
adjust reconcil ni net cash oper
amort unfavor leas oblig debt issuanc cost
amort debt discount
loss dispos fix asset
loss extinguish debt
decreas increas work capit
purchas fix asset capital-expenditure
purchas invest
sale invest
payment conting consider
net invest
proce exercis stock option warrant
proce share issu employe stock purchas plan
convers princip equiti compon convert senior
net financ
net chang equival
number except per share data
number except per share data
tysabri royalti stream fair valu
payrol relat tax
number except per share data
adjust reconcil ni net cash oper
tysabri toyalti stream chang fair valu
loss extinguish debt
impair equiti invest net
decreas increas work capit
proce royalti right
acquisit businesses/asset net cash acquir
proceed sale busi
settlement acquisition-rel foreign currenc deriv
purchas properti plant equip capital-expenditure
net invest
borrow repay revolv credit/oth net
premium earli debt retir
issuanc ordinari share
net financ
effect exchang rate chang cash/ cash equival
net chang equival
number except per share data
share assoc co
number except per share data
asset held sale
sale reserv allow
liabil held sale
tax long-term liabil
senior note loan
number except per share data
adjust reconcil ni net cash oper
impair long-liv asset
net gain loss sale long-liv assets/invest
translat adjust due venezuela devalu
research develop process
impair equiti invest net
decreas increas work capit
sale purchas busi net cash acquir
proce sale long-liv asset invest
purchas properti plant equip capital-expenditure
purchas invest asset
net invest
dividend paid ordinari share
proce issuance/ purchas ordinari share net
proce issuanc prefer share net
dividend paid prefer share
proce exercis option employe
purchas treasuri shares/ ordinari share
net financ
translat adjust cash cash equival
net chang equival
ep expect declin y/i believ well understood
investor see compound-annual-growth-rate believ endo meet con sale
ep addit mesh litig liabil unlik larg expect
conserv includ addit announc august
believ drive multipl expans stock
price target base slightli higher ebitda versu
consensu along expans ev/ebitda multipl current
drive upsid stock current level
risk includ faster expect eros vasostrict adrenalin mesh litig remain
drain cash delay time new gx launch
base larg medacorp kol interview believ could best-
in-class drug post-op pain growth opportun heron fulli
appreci street view data three separ ph studi
expect expect posit data ph instal studi bunionectomi
hernia repair abdominoplasti base previou posit ph data also look data
tka breast augment nerv block ph studi first time includ
probability-of-success po model in-lin consensu
heron cinv product -- sustol cinvanti upsid stock could come
post-op pain believ grow sale vs
consensu driven long-act post-op pain relief simpl conveni
administr potenti signific share orthoped procedur especi
painful/costli one rate outperform price target
deriv pt use dcf project cash flow
patent expir use wacc termin valu dcf consensu
outlook roughli in-lin cinv franchis
sustol growth trajectori impact reimburs hurdl ph data
robust expect addit financ need
combin amneal chang top-lin growth profil
oper margin improv low-mid-teen
driven stand-alon cost save bp addit higher margin amneal
busi bp impax brand/gener hybrid biz cost synergi amneal
combin bp see strong profit cash flow drive improv
leverag provid manag flexibl explor
use weight averag ev/ebitda multipl deriv pt
ebitda impli market view visibl drive
ipxl higher current multipl
limit visibl composit amneal portfolio cost save delay lower
durabl xyrem franchis underappreci npv xyrem
consensu -- ip strategi gener filer give time execut next-gen
strategi base medacorp survey believ xyrem line extens support
annual franchis sale despit entri gener and/or once-
nightli sodium oxyb sever oper hurdl also present
barrier pipelin help diversifi busi mix xyrem sale declin
strong cash flow low debt burden give flexibl
augment pipelin
deriv pt base dcf valuat use wacc termin
growth rate project
lose xyrem litig remain anda filer faster eros brand
xyrem trigger earlier entri gener
project top-lin growth conserv acthar
inomax sale sever regulatori commerci hurdl could prevent rapid eros
acthar inomax potenti payer/competitor price action remain wild-card assum
share eros acthar inomax interestingli believ
key overhang stock consensu estim still assum eros either
two product pipelin appear unlik diversifi busi meaning
sever year estim pipelin drive sale
look visibl acthar inomax competit late-stag pipelin readout get
construct stock
deriv pt use dcf base upon discount rate termin growth rate
reflect continu eros acthar inomax gener outer year
acthar growth may miss exceed expect may greater expect
delay entri acthar competitor could win appeal inomax ip case
compani might experi pipelin failure/ delay outcom could result
share trade price target
place market perform rate share base strong pipelin gener
biosimilar off-set continu high singl digit base gener eros support
revenu growth potenti near-term upsid consensu
number limit competit copaxon advair though difficult high
visibl balanc sheet give option capit deploy hit ep
insulin/biosimilar growth driver thatcould expand multipl
rel peer view
use weight averag ev/ebitda multipl slight expans current
level ebitda line consensu deriv price target per share
gener advair may get approv visibl time new
gener launch limit repres risk valuat
believ pacira exparel non-opioid post-op pain manag
continu grow driven commerci collabor potenti label expans
nerv block sale believ well
understood investor long-term growth may impact entri heron
potenti better clinic profil -- longer durat pain relief hour vs hour
easier administr instil vs infiltr rate pacira stock market perform mp
price target
pt base dcf forecast cash flow use
wacc termin growth rate
exparel get approv nerv block phase studi success limit impact
collabor potenti competit heron
consum healthcar america like continu grow low-singl digit
consum healthcar also grow low-singl digit growth potenti
manag initi take time play rx potenti upsid consensu
launch proair androgel limit visibl
outer year improv profit leverag ratio strong cash flow
allow look potenti bolt-on acquisit howev limit visibl
medium-/long-term growth trajectori busi dont see high potenti
out-performance drive stock meaning higher rate market perform
deriv price target base ev/ebitda multipl high end
consum peer group current level ebitda
limit rx-to-otc switch opportun delay new rx over-the-counter product launch initi
drive busi may success anticip
follow teva recent announc restructur plan believ consensu
high expect competitor copaxon expect total us gener
biz erod compound-annual-growth-rate vs con strong execut sever front
need right-siz busi cost base reduct
number year capital-expenditure reduct vs austedo
fremanezumab grow howev debt load remain
overhang despit cost reduct dividend suspens believ teva need
refin debt next year maintain minimum cash balanc
rate teva under-perform price target
ebitda consensu ev/ebitda multipl
contract drive teva lower view pt
higher expect number new gx launch key brand product austedo
fremanezumab perform expect
